文献速递乳腺癌

CDK4/6抑制剂联合氟维司群治疗HR阳性HER2阴性晚期乳腺癌的汇总总生存分析

Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
PubMed 文献 · Lancet Oncol · 2021-10-14

该探索性汇总分析纳入三项FDA已批准的III期随机试验的1960例HR阳性HER2阴性晚期或转移性乳腺癌患者,比较CDK4/6抑制剂或安慰剂联合氟维司群。

核心结论

  • 在HR阳性HER2阴性晚期或转移性乳腺癌患者中,CDK4/6抑制剂联合氟维司群较安慰剂联合氟维司群显示一致的总生存获益,支持现有标准治疗。

研究设计与样本

  • 探索性汇总分析,汇总三项FDA已批准的III期随机试验的个体患者数据,比较CDK4/6抑制剂或安慰剂联合氟维司群。
  • 共1960例患者随机分配,其中1948例接受至少一剂治疗(CDK4/6抑制剂组1296例,安慰剂组652例)。
  • 患者年龄≥18岁,ECOG体能状态0-1,HR阳性HER2阴性晚期或转移性乳腺癌。

临床怎么用

  • 对于HR阳性HER2阴性晚期或转移性乳腺癌,CDK4/6抑制剂联合氟维司群可作为标准治疗选择,总生存获益与既往无进展生存获益一致。

局限性

  • 本分析为探索性、假设生成性研究。
  • 汇总人群包含跨治疗线数的患者,因潜在异质性未报告各组中位总生存。
  • 一线内分泌治疗亚组中位OS不可估计,无法计算中位OS差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDKIs) are oral targeted agents approved for use in combination with endocrine therapy as first-line or second-line treatment of patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer. We previously reported the pooled analyses of progression-free survival in patients in specific clinicopathological subgroups, all of whom received consistent benefit from the addition of a CDKI to hormonal therapy. Here, we report the pooled overall survival results in patients treated with a CDKI and fulvestrant. METHODS: In this exploratory analysis, we pooled individual patient data from three phase 3 randomised trials of CDKI or placebo in combination with fulvestrant in patients with breast cancer submitted to the US Food and Drug Administration and approved before Aug 1, 2020, in support of marketing applications. All analysed patients were aged at least 18 years, had an Eastern Cooperative Oncology Group performance status of 0-1, had hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, and received at least one dose of CDKI or placebo in combination with fulvestrant. The median overall survival was estimated using Kaplan-Meier methods, and hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression models. Patients were analysed collectively, by number of previous lines of systemic endocrine therapy in any disease setting (first-line or endocrine naive vs second-line and later), and in various clinicopathological subgroups of interest. The estimated median overall survival was not reported by group when the pooled population included patients treated across lines of therapy because of potential patient heterogeneity. All results presented are considered exploratory and hypothesis generating. FINDINGS: Across the three pooled trials, 1960 patients were randomly assigned between Oct 7, 2013, and June 10, 2016 (12 patients were not treated and 1296 [66%] patients were randomly assigned to CDKI and 652 [33%] to placebo). In all treated patients (n=1948), the estimated HR for overall survival was 0·77 (95% CI 0·68-0·88), with a median follow-up of 43·7 months (IQR 37·8-47·7) and deaths in 935 (48%) of the 1948 patients. The difference in estimated median overall survival was 7·1 months, favouring CDKIs. In patients who received CDKIs or placebo in combination with fulvestrant as first-line systemic endocrine therapy (two trials; n=396), the estimated HR for overall survival was 0·74 (95% CI 0·52-1·07), with a median follow-up of 39·4 months (IQR 37·0-42·2). 123 (31%) of these patients died. The difference in estimated median overall survival could not be calculated because median overall survival was not estimable (95% CI 50·9-not estimable) in the CDKI group and was 45·7 months (95% CI 41·7-not estimable) in the placebo group. In patients who received CDKIs or placebo in combination with fulvestrant as second-line or later systemic endocrine therapy (three trials; n=1552), the estimated HR for overall survival was 0·77 (95% CI 0·67-0·89), with a median follow-up of 45·1 months (95% CI 39·2-48·5). 812 (52%) of these patients died. The difference in estimated median overall survival was 7·0 months, favouring CDKIs. INTERPRETATION: The addition of CDKIs to fulvestrant resulted in a consistent overall survival benefit in all pooled patients and within most clinicopathological subgroups of interest. These findings support the existing standard of care of CDKIs plus fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative, advanced breast cancer. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gao JJ, Cheng J, Prowell TM, et al. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2021. PMID: 34656225. doi:10.1016/S1470-2045(21)00472-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。